Lupus susceptibility loci on chromosome 1 have an important role in the development of autoimmunity in the New Zealand Black (NZB) mouse. We have previously shown that C57BL/6 congenic mice with an introgressed homozygous NZB chromosome 1 interval extending from B35 to 106 cM develop anti-nuclear antibodies and mild glomerulonephritis. In this study, we produced subcongenic mouse strains to localize the susceptibility loci in this interval and investigate how they promote autoimmunity. Our results indicate at least four susceptibility alleles and a suppressor allele. One allele is located in the 96-100 cM region and is sufficient to breach tolerance to chromatin. Addition of a second locus in the 88-96 cM interval enhances anti-dsDNA antibody production and promotes renal disease, which together with a third susceptibility allele in the 70-88 interval results in significant mortality. We further demonstrate the presence of a suppressor locus in the 35-70 or 100-102 cM interval that abrogates these phenotypes and an additional susceptibility allele in the 102-106 cM interval that restores a milder autoimmune phenotype. Several of these loci alter T-cell function. Thus, there is substantial genetic complexity in the NZB 35-106 cM interval, with disease reflecting a balance between susceptibility and suppressor loci.
Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by the loss of tolerance to self-antigens, particularly nuclear antigens, resulting in the production of anti-nuclear antibodies (ANA). [1] [2] [3] These antibodies form immune complexes that deposit in tissues, leading to clinical manifestations of disease such as glomerulonephritis (GN), skin rash and arthritis. Considerable insight into the immune abnormalities that lead to human SLE has been derived from the study of lupus-prone mouse strains. In particular, the New Zealand Black (NZB) mouse and its F 1 cross with the New Zealand White (NZW) mouse are considered to be excellent models of SLE. NZB mice produce IgG antissDNA, -lymphocyte and -RBC antibodies that lead to hemolytic anemia and mild GN. 4 Although these mice do not develop the severe GN that is characteristic of the (NZB Â NZW)F 1 mouse strain, they appear to possess most of the immunologic defects required as replacement of the H-2 d MHC locus of NZB mice with H-2 bm12 (as in NZB.H-2 bm12 congenic mice) is sufficient to produce this phenotype. 5 To facilitate identification of the susceptibility loci that lead to development of autoimmune disease in NZB mice, we have produced congenic mouse strains, in which a homozygous NZB chromosomal interval containing a single or small cluster of susceptibility alleles has been introgressed onto the non-autoimmune C57BL/6 (B6) background. Congenic mice with an NZB chromosome 1 interval extending from 35 to 106 cM (61.9-190.5 Mb), termed B6.NZBc1 , develop high titre IgG anti-chromatin and -ssDNA antibodies together with mild GN. This is accompanied by cellular phenotypic abnormalities including splenomegaly, increased proportions of activated T and B cells and increased numbers of germinal centers (GCs). 6 Examination of hematopoietic radiation chimeras with a mixture of B6 and B6.NZBc1 bone marrow indicated that these phenotypes arose from intrinsic B and T-cell functional defects. 7 Notably, mice with a shorter NZB chromosomal interval extending from 82 to 106 cM (161. 6-190.5 Mb; previously denoted B6.NZBc1(85-106)) demonstrated an attenuated phenotype suggesting that there was a second susceptibility locus in the 35-82 cM interval. 6 In this study, we have sought to gain further insight into the location and function of the lupus susceptibility alleles on NZB chromosome 1, through creation and investigation of additional subcongenic mouse strains. Our results indicate the presence of at least four susceptibility alleles and a suppressor allele on NZB chromosome 1. The first susceptibility allele is located within the 96-100 cM interval and contains the previously identified Slam, Ifi202 and Fcgr2b candidate gene loci. [8] [9] [10] [11] A second lupus susceptibility locus is located in the 88-96 cM interval that leads to an increased number and size of GC and promotes anti-dsDNA production and renal disease. The third lupus susceptibility allele is located in the 70-88 interval and together with the loci in the 96-100 and 88-96 cM intervals is sufficient to induce severe GN and significant mortality. We further demonstrate the presence of a suppressor locus either in the 35-70 or 100-102 cM interval that abrogates these phenotypes and an additional susceptibility allele in the 102-106 cM interval that restores a milder autoimmune disease. Functional characterization of T cells in these mice indicates that genetic loci within the 96-100 and 70-88 loci affect T-cell function, leading to enhanced production of interferon (IFN)-g, whereas the suppressor locus inhibits this production. Taken together the data indicate that there is substantial previously unrecognized genetic complexity in the NZB chromosome 1. 35-106 cM interval and that the autoimmune phenotype in these mice reflects the balance between susceptibility and suppressor alleles that function at least in part through effects on T-cell function.
Results
Characterization of the autoimmune phenotype in subcongenic mouse strains We have previously shown that congenic mice with an NZB chromosome 1 interval extending from 35-106 cM made significantly higher titres of autoantibodies and had more severe GN than mice with a 82-106 cM interval, suggesting the presence of at least two susceptibility loci: one within the 35-82 interval and the other within the 82-106 interval. 6 Based upon the absence of an autoimmune phenotype in mice with an NZB 100-109 cM interval, we hypothesized that the second susceptibility locus was located within the 82-100 interval. These results were consistent with our previous mapping study that demonstrated a broad area of linkage to several B-cell activation phenotypes with peaks at B70 and 96 cM. 12 To further investigate the location and function of these susceptibility loci additional subcongenic mice were produced (see Figure 1) , which we proposed to contain one or both of these loci.
Cohorts of mice from each subcongenic strain were aged to 4 or 8 months and autoantibody production, GN and mortality were examined. Figure 2 shows the results for ANA production at 4 months. Both B6.NZBc1(96-100) and B6.NZBc1(88-100) mice produced similar levels of anti-ssDNA antibodies indicating the presence of a susceptibility locus in the 96-100 interval. However, 4-month-old B6.NZBc1(88-100) mice produced significantly higher levels of IgG anti-dsDNA antibodies than B6.NZBc1(96-100) (P ¼ 0.0196), suggesting the presence of another lupus susceptibility locus in the 88-96 cM interval. Consistent with the presence of an additional susceptibility locus in the NZB 70-88 cM interval, B6.NZBc1(70-100) mice made significantly higher titres of autoantibodies than B6.NZBc1(88-100) and B6.NZBc1(96-100) mice. On the basis of our previous findings, this locus is most likely located within the 70-82 cM interval. 6 Notably, mice with an NZB 43-85 cM interval did not produce IgG or IgM autoantibodies, suggesting that the lupus susceptibility locus in the 43-85 cM interval is insufficient to induce a breach of tolerance to nuclear antigens.
B6.NZBc1(35-102) mice were also produced to confirm that genes in the telomeric region of NZB chromosome 1 were not involved in the generation of the autoimmune phenotype. Surprisingly, mice with a 35-102 interval produced significantly lower levels of IgG autoantibodies when compared with B6.NZBc1(35-106) mice (Figure 2 ), indicating the presence of an additional susceptibility locus in B6.NZBc1(35-106) mice. As the centromeric crossover for these two mouse strains is in the same 0.7 Mb interval between rs13475886 (30.1 cM or 61.2 Mb) and rs3158129 (30.1 cM or 61.9 Mb), it is likely that this locus is located in the 102-106 cM interval.
Notably, B6.NZBc1(35-102) mice also had significantly lower levels of IgG autoantibodies as compared with B6.NZBc1(70-100) mice ( Figure 2 ). This finding suggests the presence of a suppressor locus that is located within the NZB 35-70 or 100-102 interval.
Increased mortality and severity of kidney disease observed in B6.NZBc1(70-100) mice While the subcongenic cohorts were being aged, it was noted that a number of B6.NZBc1(70-100) mice died beginning at B3 months of age. Figure 3a shows the survival results for the subcongenic mouse strains examined. With the exception of the B6.NZBc1(70-100) strain, death of mice during the first 8 months of life was rare. In contrast, B40% of B6.NZBc1(70-100) mice died during this period. To gain insight into the immune mechanisms leading to this increased mortality, cohorts of B6.NZBc1(70-100) mice were bled every 2 weeks and monitored for development of autoantibodies, hemolytic anemia and GN. None of the mice produced significant titres of IgG anti-RBC antibodies or developed anemia. In contrast, mice that died showed an increase in blood urea nitrogen (BUN, an indicator of severe renal disease) immediately before death that was accompanied by increased production of IgG anti-dsDNA antibodies (Figure 3b ). This suggested that the deaths observed in B6.NZBc1(70-100) mice were associated with severe renal failure. Consistent with this possibility, examination of kidney sections from B6.NZBc1(70-100) mice that were pre-morbid demonstrated the presence of diffuse proliferative GN. Notably, hematuria rather than proteinuria was seen in pre-morbid mice, suggesting the presence of a nephritic rather than nephrotic picture.
To further characterize the nature and severity of kidney disease in the various subcongenic mouse strains, the kidneys of mice killed at 8 months of age were examined for IgG deposition and light microscopic changes, with the severity of the changes being graded using a four-point scale as outlined in Methods. The kidneys from 8-month-old B6.NZBc1(88-100), B6.NZBc1 (70-100) and B6.NZBc1 mice demonstrated significantly increased IgG deposition and more severe renal disease than B6 controls (Figure 4 ). Despite the death of B40% of the B6.NZBc1(70-100) mice with the most severe kidney disease before this time point, the majority of remaining mice still demonstrated severe changes with diffuse proliferative GN. In general, the severity of light microscopic changes paralleled the extent of IgG deposition, suggesting that differences in the amount and specificity of IgG autoantibodies, rather than the renal response to injury, dictated the severity of renal involvement. This concept is further supported by the observation that the mice with the most severe kidney involvement all produced significant titres of IgG anti-dsDNA antibodies, which has been closely corre- Production of ANA in subcongenic mice. Autoantibody levels in the serum of 4-month-old B6 (K), B6.NZBc1(43-85) (J), B6.NZBc1(96-100) (m), B6.NZBc1(88-100) (n), B6.NZBc1(70-100) (.), B6.NZBc1(35-102) (,) and B6.NZBc1(35-106) (E) congenic mice. An ELISA was used to assay for the presence of IgM or IgG anti-ssDNA, anti-dsDNA and anti-chromatin. Each symbol represents the determination for an individual mouse. Horizontal lines represent the mean. The P values for significant differences between the congenic mouse strains are shown over bars. Differences between congenic strains and B6 mice are indicated by asterisks with *Po0.05, **Po0.005 and ***Po0.0005. All P values were determined by the Mann-Whitney non-parametric test.
lated with the severity of renal disease in previous studies. Notably, significant renal abnormalities were not seen in B6.NZBc1(96-100) mice, suggesting the presence of an additional locus within the NZB 88-96 cM chromosome 1 interval that controls the development of renal disease in these mice. Consistent with the presence of a suppressor locus in B6.NZBc1 mice that abrogates IgG ANA production, kidney disease was significantly attenuated in these mice as compared with that seen in B6.NZBc1(70-100) mice.
Cellular abnormalities in the subcongenic mouse strains
To gain further insight into the immune mechanisms through which the various loci on NZB chromosome 1 act to facilitate or impair development of autoimmune disease, we performed an extensive cellular characterization of the various subcongenic mice at 4 months of age. All of the subcongenic mouse strains demonstrated Mice were tracked and mortality was recorded up to 8 months of age. The P values for significant differences between B6 and other congenic mouse strains are shown, **Po0.005, NS ¼ not significant as determined by the log-rank test of survival. (b) B6 and B6.NZBc1 (70-100) were monitored for the production of serum IgG anti-dsDNA Ab and the level of blood urea nitrogen (BUN) beginning at 2 months of age until 7-7.5 months of age (or until the mice died or were killed for experiments). IgG anti-dsDNA Ab were measured by ELISA and the BUN level by a colorimetric assay. Each symbol represents the determination of an individual mouse. Circles denote mice that died at the age shown. A total of 8 B6.NZBc1(70-100) mice and 4 B6 controls were monitored in the cohort study shown. 7 Changes in the size of the marginal zone population were restricted to B6.NZBc1(88-100) and B6.NZBc1(70-100) subcongenic mice, suggesting that the genetic locus (or loci) that produces this phenotype maps to the 88-96 interval.
B6.NZBc1(35-106) mice also demonstrated increased B-cell activation, reflected by increased levels of expression of B7.1, B7.2, intercellular adhesion molecule-1 (ICAM-1) and CD69, predominantly in their CD21 low(lo) B-cell compartment. As shown in Table 1 and Figure 5 , increased B-cell activation was seen in all of the subcongenic mouse strains, but was most marked in B6.NZBc1(70-100) mice. As increased B-cell activation was seen in both B6.NZBc1(96-100) and B6.NZBc1(43-85) mice, it is likely that the loci in these mice contribute additively to the increased B-cell activation observed in B6.NZBc1(70-100) mice. Notably, B-cell activation was significantly reduced in B6.NZBc1(35-102) mice and largely restored in B6.NZBc1(35-106) mice, indicating that the additional genetic loci in these mice inhibit or augment B-cell activation, respectively.
Increased proportions of recently activated (CD69 þ ) and memory/effector (CD44 hi CD62L lo ) T cells are also seen in B6.NZBc1(35-106) mice. Of the subcongenic strains examined, B6.NZBc1(96-100), B6.NZBc1(88-100) and B6.NZBc1(70-100) mice all had roughly equivalently increased levels of recently activated CD4 þ T cells, suggesting that the genetic locus that produces this phenotype is located within the 96-100 interval (Table 2 ). These mice also had increased proportions of memory/ effector T cells, consistent with chronically increased activation of their CD4 þ T-cell subset, and similar, but less pronounced findings were seen for their CD8 þ T-cell subset. Although the proportion of recently activated CD4 þ T cells in B6.NZBc1(43-85) mice was not significantly elevated, these mice had increased proportions of memory/effector CD4 þ and CD8 þ cells, suggesting that their T cells were also being chronically activated, but to a lesser extent. In contrast, B6.NZBc1(35-102) mice demonstrated a marked reduction in T-cell activation when compared with B6.NZBc1(35-106) and B6.NZBc1(70-100) mice, even though the proportion of memory T cells in B6.NZBc1(35-102) remained significantly increased relative to B6 controls. This finding suggests that the suppressor locus inhibits T-cell activation.
To further explore the nature of T cell help for autoantibody production in subcongenic mice, we quantified the number and size of GC. We have previously shown that B6.NZBc1(35-106) mice have an increased number and size of GC, as compared with control B6 mice. As shown in Figure 6 , all of the subcongenic mouse strains examined had an increased number of splenic GC, which was most marked in the B6.NZBc1(88-100), B6.NZBc1(70-100) and B6.NZBc1(35-106) mouse strains. In general, the number and size of the GC observed in these mouse strains correlated with each other and paralleled the extent of chronic T-cell activation observed by flow cytometry (see Table 2 and Figure 6 ).
A deficiency of regulatory T (Treg) cells has been implicated in the increased T-cell activation seen in mice with a chromosome 1 interval from the New Zealand Mixed (NZM) 2410 mouse strain. Therefore, we questioned whether the increased T-cell activation seen in NZB chromosome 1 congenic mice was associated with decreased proportions of Treg cells, as seen in these mice. To this end, we quantified the proportion of 
hi splenocytes, the population initially thought to represent Treg cells in previous studies. 13 As shown in Table 2 , all of the mouse strains had reduced proportions of these cells as compared with B6 mice, which achieved statistical significance for four of the mouse strains. Similar findings were also observed for 8-month-old mice (Supplementary 
Altered threshold for T-cell activation in subcongenic mice
We have previously shown that increased T-cell activation in B6.NZBc1(35-106) results from an intrinsic T-cell defect. 7 This finding suggested that the T cells of these mice have altered function. To assess this possibility and determine the location of the genetic locus (loci) that contributes to this functional abnormality, CD4 þ T cells were purified from young pre-autoimmune 8-12-weekold mice and stimulated with immobilized anti-CD3 in vitro. At this age, no significant differences in the proportion of recently activated (CD69 þ ) and memory/ effector (CD44 hi CD62L lo ) T cells are observed between mouse strains. As shown in Figure 7 , CD4 þ T cells from all subcongenic strains except B6.NZBc1(43-85) demonstrated increased proliferation at suboptimal concentrations of anti-CD3 antibody. Notably, proliferation was similarly increased in all of these strains, indicating that the increased proliferation maps to the 96-100 cM interval and that the suppressor locus does not function by inhibiting T-cell proliferation. On the other hand, all of the subcongenic mouse strains examined demonstrated increased IFN-g production with anti-CD3 monoclonal antibody (mAb). At low concentrations of anti-CD3 mAb, this increase was restricted to B6.NZBc1(70-100) T cells. These findings suggest that Horizontal lines represent the mean. The P values for significant differences between the congenic mouse strains are shown over bars. Differences between congenic strains and B6 mice are indicated by asterisks with *Po0.05, **Po0.005 and ***Po0.0005. All P values were determined by the Mann-Whitney nonparametric test.
The lupus phenotype in B6.NZBc1 congenic mice Y-H Cheung et al loci within the 43-85 and 96-100 cM intervals are associated with increased IFN-g production and that they act additively to enhance IFN-g production in B6.NZBc1(70-100) mice. IFN-g production was similarly reduced in B6.NZBc1(35-102) and B6.NZBc1(35-106) mice as compared with B6.NZBc1(70-100) mice, suggesting that the suppressor locus in the 35-102 interval impairs the generation of this cytokine and that the susceptibility locus in the 102-106 interval does not restore its production.
Discussion
The current study sought to further localize the lupus susceptibility loci on NZB chromosome 1 and to gain insight into the immune mechanisms by which they promote autoantibody production and renal disease. Through the generation of multiple subcongenic mice with overlapping chromosomal intervals, we demonstrate considerable genetic complexity in the immunopathogenesis of lupus in NZB chromosome 1 congenic mice, with at least 4 lupus susceptibility loci and a suppressor locus. Although our previous mapping study demonstrated a broad area of linkage, indicating the possibility of more that one genetic locus in this interval, 12 this extent of genetic complexity was not anticipated. Thus, the NZB chromosome 1 interval joins a growing number of congenic intervals that based upon mapping studies were thought to contain a single susceptibility locus, but upon further dissection were found to contain multiple susceptibility loci. [15] [16] [17] These findings are consistent with the concept that the original mapping studies were underpowered to detect individual genetic loci, that in general have relatively small effects, and therefore only detected regions where multiple loci interacted additively or multiplicatively to produce a stronger signal.
Our results indicate the presence of at least one lupus susceptibility locus located in the 96-100 cM (172.8-181.7 Mb) interval of NZB chromosome 1. Genetic polymorphism(s) in this interval lead to a relatively mild autoimmune phenotype with production of ANA in the absence of significant renal disease. This region overlaps with the Nba2 and Sle1b loci that were identified in NZB and NZM2410 mouse strains, 17 ,18 respectively, and contains the previously proposed candidate genes Slam, Ifi202 and Fcgr2b. [8] [9] [10] [11] The Slam locus encodes a family of adhesion/costimulatory molecules that regulate the activation threshold and type of response for many cells involved in the immune system [19] [20] [21] (and reviewed in ref. 22 ). NZB, NZM2410 and a variety of other autoimmune mouse strains share the same Slam allele, which differs from that of B6 mice. 9 Although there are polymorphisms in many of the Slam family members within this locus, recent experiments suggest that it is the polymorphism in Ly108 that alters immune function. Expression of Ly108.1, an alternatively spliced isoform of Ly108, is increased in mice with the autoimmune associated allele, whereas expression of Ly108.2 is decreased. 23 These two splice variants differ in their cytoplasmic domain, with the Ly108.1 variant demonstrating an enhanced ability to trigger SAPdependent tyrosine phosphorylation in T cells. 24 Stimulation of Ly108 with an anti-Ly108 mAb has been shown to enhance Th1 cytokine release in human T cells. 25 Thus, the increased proliferation and IFNg secretion by B6.NZBc1(96-100) T cells observed following anti-CD3 cross-linking could arise from this polymorphism.
Although Ifi202 and Fcgr2b have also been proposed as candidate genes in the NZB 96-100 interval, a recent study examining another series of subcongenic mice with NZB chromosome 1 intervals centering around this interval demonstrated that the presence or absence of the NZB Ifi202 allele had little impact on autoimmunity. 26 This group also concluded that the Fcgr2b locus augments the autoimmune phenotype, since a shorter interval containing the Slam locus alone had a milder phenotype than a longer interval containing both the Slam and Fcgr2b loci. However, the autoantibody profile of the mice with the shorter interval containing just the Slam locus is similar to that observed for our B6.NZBc1(96-100) mice that contain the Fcgr2b locus, whereas that of the longer interval is similar to our B6.NZBc1(88-100) mice (notably, both intervals have similar centromeric crossovers). These observations suggest that the second susceptibility allele in the congenic mice with the longer intervals is unlikely to be the NZB Fcgr2b allele, which appears to have little impact on the autoimmune phenotype.
The second lupus susceptibility locus located in the 88-96 cM interval (170.3-172.8 Mb) leads to an increased number and size of GC and promotes anti-dsDNA Ab production and renal disease. These findings suggest that this locus has an impact on qualitative aspects of T-cell help. This interval overlaps with the Sle1a susceptibility locus, previously identified in NZM2410 mice. B6.Sle1a mice have several T-cell abnormalities, including increased T-cell activation, reduced numbers and function of Treg cells and increased CD4 þ T cell support for IgG anti-chromatin production by B cells. 17, 27 Although the predicted function of the NZB susceptibility locus in the 88-96 cM interval is consistent with that of Sle1a, the proportion of CD4 Table  1 ). Given that the proportion of CD4 þ Foxp3 þ cells is reduced in B6.Sle1a mice, the susceptibility locus in NZB mice appears to be distinct from Sle1a.
Within the 88-96 cM interval, there are 23 known genes of which the gene SH2 domain-containing protein 1B (Sh2d1b), encoding the EAT-2A adapter protein that binds to the cytoplasmic tails of SLAM, CD224, CD84 and Ly108, represents the most attractive candidate. EAT-2A is mainly expressed in natural killer cells (but also in B cells, mast cells and macrophages) and has been shown to inhibit natural killer-cell function through tyrosine phosphorylation. 31, 32 In fact, Sh2d1b-deficient mice (EAT-2A À/À ) exhibited enhanced natural killer-cell cytotoxicity as well as increased IFN-g secretion upon stimulation with anti-CD16, NKG2D, Ly49D and CD224. 32 Notably, Sh2d1b is highly polymorphic with at least 76 known single nucleotide polymorphisms in various mouse strains, increasing the likelihood that polymorphisms between B6 and NZB mice exist. Although this gene has also been proposed as a candidate gene for the Sle1a locus, given the different phenotypes in B6.NZBc1(88-100) and B6.Sle1a mice, it appears unlikely that the same variant promotes disease in both strains.
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A third susceptibility locus is located in the 70-88 cM interval (127.5-170.3 Mb). The addition of this locus to those in the 88-100 cM interval resulted in increased B-cell activation, autoantibody titres, kidney immunoglobulin deposition, severity of renal disease and mortality. It is likely that this locus is centromeric to B162 Mb, because we previously showed that B6.NZBc1(35-106) mice have a more pronounced phenotype than B6.NZBc1(85-106) mice. 6 This region corresponds to the area of peak linkage for IgG anti-ssDNA Ab production and increased expression of ICAM-1 and CD44 on B cells in our previous mapping study. 12 It also overlaps with an NZB region identified by Kono et al. 33 that is linked to anti-chromatin Ab production and splenomegaly in a (NZB x NZW)F 2 cross. By itself (see B6.NZBc1(43-85) mice), this locus appears to be insufficient to breach B-cell tolerance to nuclear antigens, but does lead to an increase in memory/effector T cells and GC that are small in size. These findings, together with the observation that this locus is associated with increased IFN-g production following anti-CD3 stimulation, suggest that this locus affects T-cell function. Within the 70-82 cM interval, there are 268 known and predicted genes among which Cxcr4, Ctse and Ptprv represent attractive candidate genes. Roquin is also located on chromosome 1 and sanroque mice carrying a M199R mutation in the Roquin protein exhibit a lupus-like phenotype including the generation of ANAs and GN. 34 However, this gene is located telomeric to the cross-over in B6.NZBc1(85-106) mice, making it a less attractive candidate.
Autoimmune disease is markedly attenuated in B6.NZBc1(35-102) mice as compared with B6.NZBc1 (70-100) mice. It is unlikely that this difference reflects the absence of one or more susceptibility loci in B6.NZBc1(35-102) mice, because extensive genotyping of this interval revealed NZB homozygosity with the largest distance between markers of 4.4 Mb. It is also unlikely that this difference results from genetic differences on other chromosomes that may have been missed by using a speed congenic approach. Several different transgenes and knockouts have been crossed onto the B6.NZBc1(70-100) background, with homozygous wildtype mice always retaining the severe autoimmune phenotype. In addition, both the B6.NZBc1(35-102) and B6.NZBc1(35-106) mouse strains demonstrate an attenuated autoimmune phenotype. Although both of these mouse strains originated from the same original cross, they were backcrossed independently to B6 a number of generations before intercrossing to produce homozygous mice, arguing that they are unlikely to share a suppressor locus that is not on chromosome 1. Comparison of immunologic function in B6.NZBc1(70-100) and B6.NZBc1(35-102) mice suggests that the suppressor locus affects T-cell function. B6.NZBc1 retained the ability to produce IgM ANA, suggesting that the breach of B-cell tolerance to nuclear antigens remains. However, IgG ANA production and the number of GC were markedly attenuated, indicating a relative lack of T-cell help. This occurred despite the observation that their T cells retained increased IFNg production and increased proliferation in response to anti-CD3 crosslinking, as compared with control B6 mice.
Comparison of B6.NZBc1(35-106) and B6.NZBc1 (35-102) mice demonstrates the presence of another ) for 72 h. Cell proliferation was measured using CFSE dilution. ELISA assays were performed to measure the amount of IFN-g produced by CD4
þ T cells after 72 h of culture. Error bars indicate the s.d. The P values for significant differences between the mouse strains are shown, *Po0.05, **Po0.005 and ***Po0.0005, and were determined by one-way ANOVA followed by Dunnett's Multiple Comparison Test. susceptibility allele. It is unlikely that this susceptibility allele is located at the centromeric end of the 35-106 cM interval, because we have narrowed the crossover to the same 0.7 Mb interval for both of these mouse strains, which does not contain any genes known to have immunologic function. It is therefore probable that the 102-106 cM (187. 7-191.4 Mb) interval contains this susceptibility allele. This interval excludes Sle1c, an NZM susceptibility allele, found on the telomeric end of chromosome 1, but contains Tgfb2, an attractive candidate gene. 17 This susceptibility allele appears to be unable to breach B-cell tolerance to nuclear antigens on its own, as we have previously shown that B6.NZBc1 (100-109) mice do not produce ANA. 6 Nevertheless, B6.NZBc1(100-109) mice had elevated levels of MHC on their B cells and showed a trend to increased expression of CD69 on their T cells, suggesting that they may have some underlying cellular abnormalities as compared with B6 mice.
In summary, we have identified several novel susceptibility loci and an intriguing suppressor locus on NZB chromosome 1. Further characterization of these loci and the immune mechanisms by which they interact to facilitate or inhibit autoimmunity should provide new insights into the pathogenesis of lupus.
Methods
Mice B6 and NZB mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and Harlan-SpragueDawley (Blackthorne, England), respectively, and subsequently bred in our facility. Congenic mice were produced by backcrossing mice with an NZB chromosome 1 interval onto the B6 background, using the speed congenic technique. Mice were typed at each successive generation using polymorphic microsatellite markers that discriminate between NZB and B6 DNA, spaced at B20 cM intervals throughout the genome except for regions containing lupus susceptibility genes where more densely spaced markers were used. Fully backcrossed mice were obtained in six generations and then intercrossed to produce congenic mice that were homozygous for the NZB intervals. The original chromosome 1 congenic mouse that was generated (B6.NZBc1 (35- (Figure 1 ). These were then intercrossed to produce homozygous mice. All mice were housed in microisolators in the animal facility at the Toronto Western Hospital (Toronto, ON, Canada) and were specific-pathogen free. The mice that were examined in this study were all female. Following washing, allophycocyanin-conjugated streptavidin (BD PharMingen, San Diego, CA, USA) was used to reveal biotin-conjugated Ab staining. Dead cells were excluded by staining with 0.6 mg ml À1 propidium iodide (PI; Sigma-Aldrich). Flow cytometry of the stained cells was performed using a dual laser FACScalibur (BD Biosciences, Mountain View, CA, USA) and analyzed using Cell Quest Pro software (BD Biosciences). Live cells were gated on the basis of PI exclusion and scattering characteristics with 10 000 events being acquired for each sample. The following directly conjugated mAbs were purchased from BD PharMingen: biotin conjugated anti-CD11c (N418), -CD11b (Mac1), -CD4 (L3T4), -CD8 (53-6.7) and -CD62L (MEL-14) ; PE conjugated anti-B7.1 (16-10A1), -B7.2 (GL1), -CD3 (145-2C11), -CD69 (H1.2F3), -CD44 (IM7), -NK1.1 (PK136) and -CD4 (H129.19); and fluorescein isothiocyanate (FITC) conjugated anti-CD3 (145-2C11), -CD4 (L3T4), -CD8 (53-6.7), -CD21/CD35 (7G6), -CD25 (7D4), -B220 (RA3-6B2), -CD11c (HL3) and -CD11b (M1/70). FITC anti-CD62L was purchased from Cedarlane (Hornby, ON, Canada). All isotype controls, with the exception of hamster IgG controls (BD PharMingen), were purchased from Cedarlane.
CD4
þ T-cell isolation CD4 þ T cells were isolated using the Dynal Mouse CD4 Negative Isolation Kit (114.15D, Invitrogen Dynal AS, Oslo, Norway). In brief, single-cell suspensions of RBCdepleted splenocytes (100 Â 10 6 cells per ml) were suspended in 10% fetal bovine serum (FBS)/phosphatebuffered saline (PBS) and incubated with a cocktail of biotinylated antibodies on ice for 20 min. Excess antibodies were removed by washing and the cells resuspended in 10% FBS/PBS at a concentration of 100 Â 10 6 cells per ml. Streptavidin-conjugated Dynabeads were washed with PBS to remove azide, resuspended and added to the cell suspension and incubated at room temperature for 15 min. CD4 þ T cells were then purified by negative selection with a magnet and resuspended in RPMI1640 containing 0.5% normal mouse serum (NMS). The resultant cell population contained more than 90% CD4 þ T cells.
Anti-CD3 T-cell proliferation
Purified CD4 þ T cells were loaded with 5 mM carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR, USA) by incubating 5 Â 10 7 cells per ml with CFSE for 10 min at 37 1C. Labeling was quenched with one wash of ice-cold 10% FBS/RPMI1640 and one wash of ice-cold RPMI1640.
CFSE labeled CD4 þ T cells were then resuspend in 0.5% NMS/RPMI1640 and cultured at 2.5 Â 10 5 cells per well for 72 h at 37 1C in 96-well flat bottom plates with 0.1 mg ml À1 to 10 mg ml À1 of immobilized anti-CD3 antibody (Cedarlane) in the presence or absence of 1 mg ml À1 of anti-CD28 antibody (BD Pharmingen). Proliferation was measured by CFSE dilution using flow cytometry.
Cytokine assays
Cytokine levels in tissue culture supernatants were measured at 72 h. Anti-IL-2, -IL-4 and -IFN-g capture antibodies, biotinylated-anti-IL-2, -IL-4 and -IFN-g detection antibodies, and recombinant IL-2, IL-4 and IFN-g were purchased from BD Pharmingen. Assays were performed as per the manufacturer's recommendations. The concentration of cytokine in each supernatant was calculated from a standard curve of absorbance versus concentration of recombinant cytokine.
Measurement of Ab production
Serum levels of IgM and IgG anti-chromatin, -dsDNA and -ssDNA Abs were measured by ELISA. The ssDNA was prepared by boiling dsDNA (isolated from calf thymus DNA) for 10 min and quick cooling on ice for 2 min. H1-stripped chromatin was prepared from chicken RBC, as described previously. 35 ELISA plates were coated overnight with chromatin (8 mg ml À1 ), dsDNA (40 mg ml
À1
) or ssDNA (20 mg ml À1 ) diluted in PBS at 4 1C. The plates were then washed with 0.05% Tween 20/PBS, and blocked with 2% BSA/PBS for 1 h at room temperature. After further washing serum samples, diluted 1/100 in PBS/BSA/Tween 20, were added. Bound antibodies were detected using alkaline phosphatase-conjugated anti-IgG or anti-IgM (Caltag, Burlingame, CA, USA) as secondary reagents. For measurement of total IgM and IgG, plates were coated with goat anti-mouse IgM and IgG (Jackson ImmunoResearch, West Grove, PA, USA), respectively, and the serum was diluted 1/1000. The amount of bound IgM or IgG was calculated from a standard curve using purified class-specific controls, and the Ab concentration was calculated from a plot of concentration versus absorbance.
Anti-RBC Ab production was assessed by flow cytometry. Heparinized blood was washed twice in 2% FBS in PBS and stained with FITC anti-IgM (Caltag), antiIgG (Caltag) or -hamster IgG as an isotype control (BD Pharmingen).
Immunofluorescence staining of tissue sections Spleens were snap frozen in OCT compound (Sakura Finetek, Torrance, CA, USA) at the time of killing. Cryostat sections (5 mm) were fixed in acetone, washed with PBS and blocked with 5% normal goat serum/PBS. Sections were stained with biotinylated-PNA (SigmaAldrich) and FITC anti-B220 to detect GC. Biotin staining was revealed using rhodamine-conjugated streptavidin as a secondary reagent (Molecular Probes). Stained sections were mounted with Mowiol (Calbiochem, La Jolla, CA, USA) and tissue fluorescence visualized using a Zeiss Axioplan 2 imaging microscope (Oberkochen, Germany). Digital images were obtained using the manufacturer's imaging system. GC size was quantified using Image J software (http://rsbweb.nih.gov/ij/).
Grading of kidney sections
Kidneys were fixed in formalin, paraffin embedded, sectioned (3 mm) and stained with periodic acid-Schiff (PAS). Grading was performed by a renal pathologist (G. Lajoie) blinded to the strain of origin of the tissue section. The grading scale used for light microscopy was as follows: grade 0, normal glomeruli; grade 1, mesangial expansion and/or proliferation; grade 2, focal segmental (endocapillary) proliferative GN; grade 3, diffuse (endocapillary) proliferative GN; and grade 4, diffuse proliferative GN with crescents. Glomerular staining of kidney sections stained with FITC anti-IgG were graded by immunofluorescence microscopy. Sections with no or only trace deposits were graded as 0; those with mesangial deposits, grade 1; those with mesangial and segmental capillary wall deposits, grade 2; those with diffuse mesangial and capillary wall deposits, grade 3; and those with crescents, grade 4.
Statistics
Statistical significance of comparisons between groups of mice was determined using the Mann-Whitney nonparametric test except when comparing renal scores between experimental groups where a w
